<DOC>
	<DOC>NCT00266032</DOC>
	<brief_summary>The purpose of the study is to determine safety and efficacy of long-cycle regimens of an oral contraceptive.</brief_summary>
	<brief_title>Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG (BSP AG), Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial. The previously posted secondary Outcome Measure "Parameters of safety and tolerability" has been removed from result posting as it is covered by the Adverse Event section.</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Betadex</mesh_term>
	<criteria>Healthy women who desire contraception smokers â‰¤ 30 Years old Contraindication against use of hormonal contraceptives</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>